SG Americas Securities LLC Boosts Position in Novavax, Inc. (NASDAQ:NVAX)

SG Americas Securities LLC boosted its holdings in Novavax, Inc. (NASDAQ:NVAXGet Rating) by 101.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 31,945 shares of the biopharmaceutical company’s stock after purchasing an additional 16,080 shares during the quarter. SG Americas Securities LLC’s holdings in Novavax were worth $581,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Exchange Traded Concepts LLC purchased a new position in Novavax in the second quarter valued at approximately $47,000. Forsta AP Fonden purchased a new position in Novavax in the second quarter valued at approximately $103,000. US Bancorp DE raised its holdings in Novavax by 9.0% in the second quarter. US Bancorp DE now owns 2,270 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 187 shares during the period. Geneos Wealth Management Inc. raised its holdings in Novavax by 14.4% in the second quarter. Geneos Wealth Management Inc. now owns 2,070 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 261 shares during the period. Finally, Virtus ETF Advisers LLC raised its stake in shares of Novavax by 190.9% during the second quarter. Virtus ETF Advisers LLC now owns 2,679 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 1,758 shares during the period. Hedge funds and other institutional investors own 45.70% of the company’s stock.

Analyst Upgrades and Downgrades

NVAX has been the topic of a number of analyst reports. HC Wainwright dropped their price objective on shares of Novavax from $207.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday, December 30th. Jefferies Financial Group initiated coverage on shares of Novavax in a research note on Friday, December 2nd. They set a “hold” rating on the stock. Cowen dropped their price objective on shares of Novavax to $55.00 in a research note on Thursday, October 13th. B. Riley dropped their price objective on shares of Novavax from $74.00 to $37.00 and set a “buy” rating on the stock in a research note on Monday, January 9th. Finally, StockNews.com upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, November 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $92.50.

Novavax Price Performance

Novavax stock opened at $11.55 on Monday. The company has a market cap of $906.72 million, a PE ratio of -0.67 and a beta of 1.89. The company has a fifty day moving average price of $14.21 and a two-hundred day moving average price of $27.69. Novavax, Inc. has a 12 month low of $8.75 and a 12 month high of $101.39.

Novavax (NASDAQ:NVAXGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of $2.21 by ($4.36). The business had revenue of $734.58 million for the quarter, compared to analysts’ expectations of $555.50 million. Novavax’s revenue for the quarter was up 310.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($4.31) earnings per share. Equities research analysts anticipate that Novavax, Inc. will post -7.49 earnings per share for the current year.

About Novavax

(Get Rating)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Featured Articles

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAXGet Rating).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.